Major drugmaker tracks Real-World eczema drug safety in korea
NCT ID NCT05391061
Summary
This study is monitoring the safety and effectiveness of the approved eczema medication Cibinqo (abrocitinib) in real-world medical practice in Korea. It will follow about 1,100 patients, aged 12 and older with moderate to severe atopic dermatitis, for approximately one year after they start the prescribed treatment. The goal is to collect information on side effects and how well the drug works outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Tower
RECRUITINGSeoul, 04631, South Korea
Conditions
Explore the condition pages connected to this study.